Esperion Therapeutics Inc.
NASDAQ:ESPR 10:11:10 AM EDT
Market Cap (Intraday) | 335.74M |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | 39.4 |
10-Day MA | $2.07 |
50-Day MA | $2.40 |
200-Day MA | $1.79 |
Esperion Therapeutics Inc. Stock, NASDAQ:ESPR
3891 Ranchero Drive, Suite 150, Ann Arbor, Michigan 48108
United States of America
Phone: +1.734.887.3903
Number of Employees: 240
Description
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.